Fude Yang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Fude Yang has a total of 172 co-authors. Here are the top co-authors by number of shared publications:
Zhiren Wang
Beijing Huilongguan Hospital, Peking University Huilonguan Clinical Medical School, Beijing, China
10 shared publicationsBotao Ma
Beijing Huilongguan Hospital, Peking University Huilonguan Clinical Medical School, Beijing, China
8 shared publications- Min Liu
Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, China
7 shared publications - Yunlong Tan
Peking University HuiLongGuan Clinical Medical School, Beijing Huilongguan Hospital, Capital Medical University, Beijing, P. R. China
7 shared publications Juan Li
Beijing Geriatric Hospital, Beijing, China
6 shared publications- Huimei An
Psychiatry Research Center, HuiLongGuan Clinical Medical School, Beijing HuiLongGuan Hospital, Peking University, Beijing, China
5 shared publications
Latest Publications
- Open Access
- 20 March 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (12) , e46908
Clinical evaluation of Dachai Wendan Decoction in the treatment of metabolic syndrome induced by atypical antipsychotics: A retrospective study
: This retrospective study evaluated the clinical effectiveness and safety of Dachai Wendan Decoction (DWD) in combination with standard Western Medicine (WM) for the management of metabolic syndrome (MetS) induced by atypical antipsychotic medications. A total of 107 patients diagnosed with schizophrenia according to the International Classification of Diseases, Tenth Revision, and fulfilling the International Diabetes Federation criteria for MetS, were included between January 2020 and December 2024. Patients were allocated to either the WM group (n = 56) or the integrative medicine group receiving DWD in addition to WM (DWD + WM, n = 51). After 8 weeks of treatment, the remission rate of MetS was significantly higher in the DWD + WM group (47.1%) compared with the WM group (25.0%, P = .02). The DWD + WM group demonstrated greater reductions in body weight, body mass index, waist circumference, and blood pressure. Improvements in lipid metabolism were also more pronounced, with greater decreases in triglycerides, total cholesterol, and low-density lipoprotein cholesterol, alongside an increase in high-density lipoprotein cholesterol. Glycemic control, reflected by fasting plasma glucose and glycated hemoglobin, also improved significantly. Psychiatric symptoms remained stable in both groups, with no dosage adjustments of antipsychotics required. Both treatments were well tolerated, and the incidence of adverse events was low and comparable. These findings indicate that adjunctive therapy with DWD is a safe and effective strategy to improve metabolic outcomes in patients with antipsychotic-induced MetS.
- 20 March 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (12) , e46908
Open AccessClinical evaluation of Dachai Wendan Decoction in the treatment of metabolic syndrome induced by atypical antipsychotics: A retrospective study
: This retrospective study evaluated the clinical effectiveness and safety of Dachai Wendan Decoction (DWD) in combination with standard Western Medicine (WM) for the management of metabolic syndrome (MetS) induced by atypical antipsychotic medications. A total of 107 patients diagnosed with schizophrenia according to the International Classification of Diseases, Tenth Revision, and fulfilling the International Diabetes Federation criteria for MetS, were included between January 2020 and December 2024. Patients were allocated to either the WM group (n = 56) or the integrative medicine group receiving DWD in addition to WM (DWD + WM, n = 51). After 8 weeks of treatment, the remission rate of MetS was significantly higher in the DWD + WM group (47.1%) compared with the WM group (25.0%, P = .02). The DWD + WM group demonstrated greater reductions in body weight, body mass index, waist circumference, and blood pressure. Improvements in lipid metabolism were also more pronounced, with greater decreases in triglycerides, total cholesterol, and low-density lipoprotein cholesterol, alongside an increase in high-density lipoprotein cholesterol. Glycemic control, reflected by fasting plasma glucose and glycated hemoglobin, also improved significantly. Psychiatric symptoms remained stable in both groups, with no dosage adjustments of antipsychotics required. Both treatments were well tolerated, and the incidence of adverse events was low and comparable. These findings indicate that adjunctive therapy with DWD is a safe and effective strategy to improve metabolic outcomes in patients with antipsychotic-induced MetS.
- Open Access
- 5 February 2026
- Published by Frontiers Media SA in Frontiers in Psychiatry
- Vol. 16, 1740789
Efficacy and safety of toludesvenlafaxine hydrochloride sustained-release tablets in depression with ineffective or partially effective initial antidepressant treatment: a single-arm, multicenter clinical study
Purpose: Depression is one of the leading causes of avoidable suffering worldwide, and over 50% of patients do not respond to their first antidepressant treatment, which underscores the need for more effective alternatives. This clinical predicament urgently requires an effective solution. The core objective of this study is to clarify the clinical efficacy and application value of the triple reuptake inhibitor toludesvenlafaxine in patients with poor response to the first antidepressant therapy, providing a new basis for treatment options for this refractory group. Methods: This multicenter study included 61 patients meeting Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition ( DSM-V ) criteria for depression. All patients still had a Montgomery Depression Rating Scale (MADRS) score of ≥24 after 4 weeks of treatment with an adequate single initial antidepressant, and were clearly classified as an ineffective or partially effective initial antidepressant treatment. Patients were switched to toludesvenlafaxine for an 8-week treatment period. The primary outcome measure was the change in MADRS score from baseline to 8 weeks. The secondary outcome measures included the changes in the scores of the Hamilton Anxiety Scale (HAMA), the Dimensional Anhedonia Rating Scale (DARS), the Quality of Life Enjoyment and Satisfaction Questionnaire, Short Form (Q-LES-Q-SF), and the Clinical Global Impression of Severity Scale (CGI-S) from baseline to 8 weeks. Results: For such patients that did not respond to the first treatment, significant and rapid efficacy was demonstrated after switching to toludesvenlafaxine. At 8 weeks of treatment, the average MADRS score of the patients decreased by 15.5 points compared with the baseline (95% CI, −17.7 to −13.3; p < 0.0001; Cohen’s d = 2.35). Forty-three percent of them met the clinical remission, and 67% achieved a clinical response. More clinically significant is that the therapeutic effect emerged at an early stage—2 weeks (95% CI, −9.4 to −6.4; p < 0.0001; Cohen’s d = 1.52) and 4 weeks (95% CI, −13.3 to −9.8; p < 0.0001; Cohen’s d = 2.11). After 2 weeks of treatment, there were statistically significant differences in the HAMA, Q-LES-Q-SF, and CGI-S scores at each time point compared with the baseline. The improvement in the DARS score was statistically significant from 4 weeks. In terms of safety, the most common adverse reactions were palpitations, constipation, nausea, vomiting, hypoesthesia, and dizziness, which are mostly mild to moderate and controllable. In particular, the drug significantly improved sexual dysfunction (95% CI, −4.3 to −0.7; p = 0.0071), which is crucial for improving treatment compliance. Conclusion: This study confirmed that toludesvenlafaxine not only has significant clinical efficacy (including early onset, high remission, and response) for patients with depression who did not respond to the first antidepressant treatment, but also has good safety and can improve sexual dysfunction that affects compliance. This result highlights the significant position of toludesvenlafaxine in addressing the key clinical challenge of first treatment failure, providing a highly valuable new option for the subsequent treatment of such patients.
- 5 February 2026
- Published by Frontiers Media SA in Frontiers in Psychiatry
- Vol. 16, 1740789
Open AccessEfficacy and safety of toludesvenlafaxine hydrochloride sustained-release tablets in depression with ineffective or partially effective initial antidepressant treatment: a single-arm, multicenter clinical study
Purpose: Depression is one of the leading causes of avoidable suffering worldwide, and over 50% of patients do not respond to their first antidepressant treatment, which underscores the need for more effective alternatives. This clinical predicament urgently requires an effective solution. The core objective of this study is to clarify the clinical efficacy and application value of the triple reuptake inhibitor toludesvenlafaxine in patients with poor response to the first antidepressant therapy, providing a new basis for treatment options for this refractory group. Methods: This multicenter study included 61 patients meeting Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition ( DSM-V ) criteria for depression. All patients still had a Montgomery Depression Rating Scale (MADRS) score of ≥24 after 4 weeks of treatment with an adequate single initial antidepressant, and were clearly classified as an ineffective or partially effective initial antidepressant treatment. Patients were switched to toludesvenlafaxine for an 8-week treatment period. The primary outcome measure was the change in MADRS score from baseline to 8 weeks. The secondary outcome measures included the changes in the scores of the Hamilton Anxiety Scale (HAMA), the Dimensional Anhedonia Rating Scale (DARS), the Quality of Life Enjoyment and Satisfaction Questionnaire, Short Form (Q-LES-Q-SF), and the Clinical Global Impression of Severity Scale (CGI-S) from baseline to 8 weeks. Results: For such patients that did not respond to the first treatment, significant and rapid efficacy was demonstrated after switching to toludesvenlafaxine. At 8 weeks of treatment, the average MADRS score of the patients decreased by 15.5 points compared with the baseline (95% CI, −17.7 to −13.3; p < 0.0001; Cohen’s d = 2.35). Forty-three percent of them met the clinical remission, and 67% achieved a clinical response. More clinically significant is that the therapeutic effect emerged at an early stage—2 weeks (95% CI, −9.4 to −6.4; p < 0.0001; Cohen’s d = 1.52) and 4 weeks (95% CI, −13.3 to −9.8; p < 0.0001; Cohen’s d = 2.11). After 2 weeks of treatment, there were statistically significant differences in the HAMA, Q-LES-Q-SF, and CGI-S scores at each time point compared with the baseline. The improvement in the DARS score was statistically significant from 4 weeks. In terms of safety, the most common adverse reactions were palpitations, constipation, nausea, vomiting, hypoesthesia, and dizziness, which are mostly mild to moderate and controllable. In particular, the drug significantly improved sexual dysfunction (95% CI, −4.3 to −0.7; p = 0.0071), which is crucial for improving treatment compliance. Conclusion: This study confirmed that toludesvenlafaxine not only has significant clinical efficacy (including early onset, high remission, and response) for patients with depression who did not respond to the first antidepressant treatment, but also has good safety and can improve sexual dysfunction that affects compliance. This result highlights the significant position of toludesvenlafaxine in addressing the key clinical challenge of first treatment failure, providing a highly valuable new option for the subsequent treatment of such patients.
- Open Access
- 1 January 2025
- Published by American Association for the Advancement of Science (AAAS) in Health Data Science
- Vol. 5, 0111
Prevalence and Risk Factors of Type 2 Diabetes Mellitus among Depression Inpatients from 2005 to 2018 in Beijing, China
Background: There are few data on the comorbidity of diabetes in Chinese patients with depression. We aimed to calculate the prevalence and explore risk factors of type 2 diabetes mellitus (T2DM) among depression inpatients from 2005 to 2018 in Beijing. Methods: This study is a cross-sectional study. The data collected from 19 specialized psychiatric hospitals in Beijing were analyzed. The prevalence of T2DM and its distribution were analyzed. The multivariable logistic regression was performed to explore the risk factors of T2DM. Results: A total of 20,899 depression inpatients were included. The prevalence of T2DM was 9.13% [95% confidence interval (CI), 8.74% to 9.52%]. The prevalence of T2DM showed an upward trend with year ( P for trend < 0.001) and age ( P for trend < 0.001). The prevalence of T2DM was higher among readmitted patients (12.97%) and patients with comorbid hypertension (26.16%), hyperlipidemia (21.28%), and nonalcoholic fatty liver disease (NAFLD) (18.85%). The prevalence of T2DM in females was lower than in males among patients aged 18 to 59 years, while the prevalence of T2DM in females was higher than in males among patients aged ≥60 years. T2DM was associated with older age [adjusted odds ratios (aORs) ranged from 3.68 to 29.95, P < 0.001], hypertension (aOR, 3.01; 95% CI, 2.70 to 3.35; P < 0.001), hyperlipidemia (aOR, 1.69; 95% CI, 1.50 to 1.91; P < 0.001), and NAFLD (aOR, 1.58; 95% CI, 1.37 to 1.82; P < 0.001). Conclusions: The prevalence of T2DM among depression inpatients from 2005 to 2018 in Beijing was high and increased with the year. Depression inpatients who were older and with hypertension, hyperlipidemia, and NAFLD had a higher prevalence and risk of T2DM.
- 1 January 2025
- Published by American Association for the Advancement of Science (AAAS) in Health Data Science
- Vol. 5, 0111
Open AccessPrevalence and Risk Factors of Type 2 Diabetes Mellitus among Depression Inpatients from 2005 to 2018 in Beijing, China
Background: There are few data on the comorbidity of diabetes in Chinese patients with depression. We aimed to calculate the prevalence and explore risk factors of type 2 diabetes mellitus (T2DM) among depression inpatients from 2005 to 2018 in Beijing. Methods: This study is a cross-sectional study. The data collected from 19 specialized psychiatric hospitals in Beijing were analyzed. The prevalence of T2DM and its distribution were analyzed. The multivariable logistic regression was performed to explore the risk factors of T2DM. Results: A total of 20,899 depression inpatients were included. The prevalence of T2DM was 9.13% [95% confidence interval (CI), 8.74% to 9.52%]. The prevalence of T2DM showed an upward trend with year ( P for trend < 0.001) and age ( P for trend < 0.001). The prevalence of T2DM was higher among readmitted patients (12.97%) and patients with comorbid hypertension (26.16%), hyperlipidemia (21.28%), and nonalcoholic fatty liver disease (NAFLD) (18.85%). The prevalence of T2DM in females was lower than in males among patients aged 18 to 59 years, while the prevalence of T2DM in females was higher than in males among patients aged ≥60 years. T2DM was associated with older age [adjusted odds ratios (aORs) ranged from 3.68 to 29.95, P < 0.001], hypertension (aOR, 3.01; 95% CI, 2.70 to 3.35; P < 0.001), hyperlipidemia (aOR, 1.69; 95% CI, 1.50 to 1.91; P < 0.001), and NAFLD (aOR, 1.58; 95% CI, 1.37 to 1.82; P < 0.001). Conclusions: The prevalence of T2DM among depression inpatients from 2005 to 2018 in Beijing was high and increased with the year. Depression inpatients who were older and with hypertension, hyperlipidemia, and NAFLD had a higher prevalence and risk of T2DM.
- Open Access
- 21 June 2024
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 15, 1408915
Case report: Time response of plasma clozapine concentrations on cessation of heavy smoking
Smoking cessation in patients treated with clozapine might lead to elevated plasma concentrations and severe side effects. This case report investigated the trajectory of clozapine plasma concentrations over time after smoking cessation in a Chinese inpatient with schizophrenia. This case report delineates the temporal response of plasma clozapine concentrations and dose-corrected clozapine plasma concentrations in a 33-year-old inpatient with schizophrenia who had a substantial smoking history and ceased smoking abruptly during dose titration. This case report presents a sudden increase in plasma clozapine concentrations and dose-corrected plasma clozapine concentrations after smoking cessation, followed by a rapid decline in dose-corrected plasma clozapine concentrations during the initial 2 weeks and a return to pre-cessation levels approximately 1 month later. The findings suggest that clinicians and pharmacists should adjust clozapine dosage in accordance with changes in smoking status, taking into consideration the temporal effects. Post-smoking cessation adjustments to clozapine dosage should be coupled with therapeutic drug monitoring, especially for patients with heavy smoking habits. Moreover, the advice of the clinical pharmacist should be considered in complex cases to ensure safe use of clozapine.
- 21 June 2024
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 15, 1408915
Open AccessCase report: Time response of plasma clozapine concentrations on cessation of heavy smoking
Smoking cessation in patients treated with clozapine might lead to elevated plasma concentrations and severe side effects. This case report investigated the trajectory of clozapine plasma concentrations over time after smoking cessation in a Chinese inpatient with schizophrenia. This case report delineates the temporal response of plasma clozapine concentrations and dose-corrected clozapine plasma concentrations in a 33-year-old inpatient with schizophrenia who had a substantial smoking history and ceased smoking abruptly during dose titration. This case report presents a sudden increase in plasma clozapine concentrations and dose-corrected plasma clozapine concentrations after smoking cessation, followed by a rapid decline in dose-corrected plasma clozapine concentrations during the initial 2 weeks and a return to pre-cessation levels approximately 1 month later. The findings suggest that clinicians and pharmacists should adjust clozapine dosage in accordance with changes in smoking status, taking into consideration the temporal effects. Post-smoking cessation adjustments to clozapine dosage should be coupled with therapeutic drug monitoring, especially for patients with heavy smoking habits. Moreover, the advice of the clinical pharmacist should be considered in complex cases to ensure safe use of clozapine.
- 6 December 2023
- Published by Elsevier in Psychiatry Research
- Vol. 331, 115668
Global, regional, and national trends in incidence of depression among women, 1990-2019: An analysis of the global burden of disease study
- 6 December 2023
- Published by Elsevier in Psychiatry Research
- Vol. 331, 115668
Global, regional, and national trends in incidence of depression among women, 1990-2019: An analysis of the global burden of disease study
- Open Access
- 5 June 2023
- Published by Wiley in Brain and Behavior
- Vol. 13 (7) , e3047
White matter abnormalities are associated with the declined ability of reasoning and problem‐solving in major depressive disorder
Objectives: Executive function in people with depression is linked to the integrity of white matter fibers in the brain. We hypothesized that the maze tests in neuropsychological tests assessed reasoning and problem‐solving abilities dependent on the integrity of brain white matter fibers, and assessed this relationship using diffusion tensor imaging (DTI) in depressed patients and healthy controls.Methods: Participants aged from 18 to 50 years were recruited from Zhumadian Second People's Hospital from July 2018 to August 2019. The sample included 33 clinically diagnosed individuals with major depressive disorder (MDD) and 24 healthy volunteers (HVs). All subjects underwent Neuropsychological assessment battery (NAB) maze tests and DTI. Tract‐based spatial statistics technology in FSL software was used to process DTI data, and threshold‐free cluster enhancement (TFCE) was used to perform multiple comparison corrections. The fractional anisotropy (FA) of white matter fibers in the MDD group and HVs group were compared and extracted. Pearson correlation was used to analyze the relationship between FA and NAB scores and HAMD scores.Results: The mean NAB maze test score for the MDD group was lower than the HVs group, and the difference was statistically significant (F = 11.265, p = .037). The FA value of the body of corpus callosum and cerebral peduncle right in the depression group was lower than that in the healthy control group, and the difference was statistically significant (p < .05). FA value of the body of corpus callosum was positively correlated with NAB score (r = 0.400, p = .036), but not with the HAMD score (r = 0.065, p = .723).Conclusions: The decreased ability of reasoning and problem‐solving in MDD may be due to the decreased integrity of the white matter fibers of the body of the corpus callosum.
- 5 June 2023
- Published by Wiley in Brain and Behavior
- Vol. 13 (7) , e3047
Open AccessWhite matter abnormalities are associated with the declined ability of reasoning and problem‐solving in major depressive disorder
Objectives: Executive function in people with depression is linked to the integrity of white matter fibers in the brain. We hypothesized that the maze tests in neuropsychological tests assessed reasoning and problem‐solving abilities dependent on the integrity of brain white matter fibers, and assessed this relationship using diffusion tensor imaging (DTI) in depressed patients and healthy controls.Methods: Participants aged from 18 to 50 years were recruited from Zhumadian Second People's Hospital from July 2018 to August 2019. The sample included 33 clinically diagnosed individuals with major depressive disorder (MDD) and 24 healthy volunteers (HVs). All subjects underwent Neuropsychological assessment battery (NAB) maze tests and DTI. Tract‐based spatial statistics technology in FSL software was used to process DTI data, and threshold‐free cluster enhancement (TFCE) was used to perform multiple comparison corrections. The fractional anisotropy (FA) of white matter fibers in the MDD group and HVs group were compared and extracted. Pearson correlation was used to analyze the relationship between FA and NAB scores and HAMD scores.Results: The mean NAB maze test score for the MDD group was lower than the HVs group, and the difference was statistically significant (F = 11.265, p = .037). The FA value of the body of corpus callosum and cerebral peduncle right in the depression group was lower than that in the healthy control group, and the difference was statistically significant (p < .05). FA value of the body of corpus callosum was positively correlated with NAB score (r = 0.400, p = .036), but not with the HAMD score (r = 0.065, p = .723).Conclusions: The decreased ability of reasoning and problem‐solving in MDD may be due to the decreased integrity of the white matter fibers of the body of the corpus callosum.
- Open Access
- 15 March 2023
- Published by Springer Nature in BMC Psychiatry
- Vol. 23 (1) , 1-11
The safety and efficacy of sequential intramuscular/oral ziprasidone treatment of acute episode in patients with schizophrenia: a multicenter, open-labeled study
Ziprasidone mesylate injection is an atypical antipsychotic drug which is recently approved in China. In combination with its oral formulation, sequential therapy with ziprasidone brings new interventions to patients with agitation in the acute phase of schizophrenia. The purpose of this 7-day multicenter study conducted in China was to evaluate the efficacy and safety of ziprasidone sequential treatment through intramuscular/oral routes in agitated patients with schizophrenia. A total of 95 patients were enrolled from three centers in this study. The study duration was 7 days. In the first 3 days, subjects were administered an intramuscular injection of ziprasidone 10–40 mg daily and started sequentially with oral ziprasidone 40–80 mg at dinner (or lunch) from the day of the last intramuscular injection. In the following 4 days, according to the severity of the symptoms and the drug response, 120–160 mg of ziprasidone was orally administered daily. In total, six visits were scheduled to assess the Positive and Negative Syndrome Scale (PANSS), the Behavioral Activity Rating Scale (BARS), the Clinical Global Impression of Severity (CGI-S), and Improvement (CGI-I) scores throughout the procedure. Lastly, adverse events were recorded during treatment. Out of the 95 patients that were enrolled, 83 cases were effectively completed. Visits 3, 4, 6, PANSS, and PANSS-excited component (PANSS-EC) subscale points, and Visit 2–Visit 6 viewpoints, BARS scale points, and baseline scores denote a progressive downward trend (P < 0.001). In this study, 62 adverse events were reported. The most common adverse events were extrapyramidal symptoms (EPS) (23 cases) and excessive sedation(10 cases), and 13 cases of prolonged QTc interval were reported. Ziprasidone IM demonstrated significant and rapid reduction in agitation, and sequential oral formulation keep stability and continuation of the treatment can further ensure efficacy. Ziprasidone sequential therapy may provide a new approach to acute agitation in schizophrenic patients. The Chinese Clinical Trials Registry; URL: https://www.chictr.org.cn: ChiCTR-OIC-16007970.
- 15 March 2023
- Published by Springer Nature in BMC Psychiatry
- Vol. 23 (1) , 1-11
Open AccessThe safety and efficacy of sequential intramuscular/oral ziprasidone treatment of acute episode in patients with schizophrenia: a multicenter, open-labeled study
Ziprasidone mesylate injection is an atypical antipsychotic drug which is recently approved in China. In combination with its oral formulation, sequential therapy with ziprasidone brings new interventions to patients with agitation in the acute phase of schizophrenia. The purpose of this 7-day multicenter study conducted in China was to evaluate the efficacy and safety of ziprasidone sequential treatment through intramuscular/oral routes in agitated patients with schizophrenia. A total of 95 patients were enrolled from three centers in this study. The study duration was 7 days. In the first 3 days, subjects were administered an intramuscular injection of ziprasidone 10–40 mg daily and started sequentially with oral ziprasidone 40–80 mg at dinner (or lunch) from the day of the last intramuscular injection. In the following 4 days, according to the severity of the symptoms and the drug response, 120–160 mg of ziprasidone was orally administered daily. In total, six visits were scheduled to assess the Positive and Negative Syndrome Scale (PANSS), the Behavioral Activity Rating Scale (BARS), the Clinical Global Impression of Severity (CGI-S), and Improvement (CGI-I) scores throughout the procedure. Lastly, adverse events were recorded during treatment. Out of the 95 patients that were enrolled, 83 cases were effectively completed. Visits 3, 4, 6, PANSS, and PANSS-excited component (PANSS-EC) subscale points, and Visit 2–Visit 6 viewpoints, BARS scale points, and baseline scores denote a progressive downward trend (P < 0.001). In this study, 62 adverse events were reported. The most common adverse events were extrapyramidal symptoms (EPS) (23 cases) and excessive sedation(10 cases), and 13 cases of prolonged QTc interval were reported. Ziprasidone IM demonstrated significant and rapid reduction in agitation, and sequential oral formulation keep stability and continuation of the treatment can further ensure efficacy. Ziprasidone sequential therapy may provide a new approach to acute agitation in schizophrenic patients. The Chinese Clinical Trials Registry; URL: https://www.chictr.org.cn: ChiCTR-OIC-16007970.
- 14 February 2023
- Published by SAGE Publications in Journal of Child and Adolescent Psychopharmacology
- Vol. 33 (1) , 27-33
Relationship Between Plasma Aripiprazole and Dehydroaripiprazole Concentrations and Prolactin Levels in Chinese Children and Adolescents
Objective: To investigate the relationship between plasma aripiprazole (ARI) and its metabolite dehydroaripiprazole (DARI) concentrations and prolactin (PRL) levels in Chinese children and adolescents. Methods: This was a retrospective cross-sectional study and the data were collected at Beijing HuiLongGuan Hospital, a Beijing City owned psychiatric hospital, between January 1 and December 31, 2021. Fifty-two child and adolescent inpatients (17 males, 35 females) aged 13–18 years and received ARI regardless of diagnosis were included. The steady-state ARI and DARI plasma concentrations were measured using high-performance liquid chromatography-tandem mass spectrometry. The serum PRL levels were measured by chemiluminescence immunoassay. Results: The plasma concentrations of ARI, DARI, and the total of ARI and DARI were negatively correlated with serum PRL levels in female children and adolescents. Approximately 15% of child and adolescent inpatients treated with ARI exhibited subnormal PRL serum levels. Conclusions: The results suggest that in addition to regularly monitoring PRL levels, therapeutic drug monitoring for ARI and its main metabolite DARI can help to mitigate the adverse medical consequences associated with PRL reduction. Thus, clinicians should consider the ARI-induced reduction of PRL levels when prescribing ARI to child and adolescent patients, particularly among females.
- 14 February 2023
- Published by SAGE Publications in Journal of Child and Adolescent Psychopharmacology
- Vol. 33 (1) , 27-33
Relationship Between Plasma Aripiprazole and Dehydroaripiprazole Concentrations and Prolactin Levels in Chinese Children and Adolescents
Objective: To investigate the relationship between plasma aripiprazole (ARI) and its metabolite dehydroaripiprazole (DARI) concentrations and prolactin (PRL) levels in Chinese children and adolescents. Methods: This was a retrospective cross-sectional study and the data were collected at Beijing HuiLongGuan Hospital, a Beijing City owned psychiatric hospital, between January 1 and December 31, 2021. Fifty-two child and adolescent inpatients (17 males, 35 females) aged 13–18 years and received ARI regardless of diagnosis were included. The steady-state ARI and DARI plasma concentrations were measured using high-performance liquid chromatography-tandem mass spectrometry. The serum PRL levels were measured by chemiluminescence immunoassay. Results: The plasma concentrations of ARI, DARI, and the total of ARI and DARI were negatively correlated with serum PRL levels in female children and adolescents. Approximately 15% of child and adolescent inpatients treated with ARI exhibited subnormal PRL serum levels. Conclusions: The results suggest that in addition to regularly monitoring PRL levels, therapeutic drug monitoring for ARI and its main metabolite DARI can help to mitigate the adverse medical consequences associated with PRL reduction. Thus, clinicians should consider the ARI-induced reduction of PRL levels when prescribing ARI to child and adolescent patients, particularly among females.
- Open Access
- 21 June 2022
- Published by Frontiers Media SA in Frontiers in Psychiatry
- Vol. 13, 930457
Relationship Between Plasma Olanzapine and N-Desmethyl-Olanzapine Concentration and Metabolic Parameters in Patients With Schizophrenia
Objectives: The aim of the present study was to investigate a potential relationship between metabolic parameters and steady-state plasma concentrations of olanzapine (OLA) and its metabolite, 4-N'-desmethyl-olanzapine (DMO) in patients with schizophrenia taking therapeutic doses.Methods: A total of 352 inpatients, diagnosed with schizophrenia according to the DSM-V criteria and treated with OLA, were investigated. The plasma concentrations of OLA and DMO were measured by high-performance liquid chromatography-mass spectrometry (HPLC-MS/MS). Fasting blood samples were measured for insulin, glucose, total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-c), low-density lipoprotein cholesterol (LDL-c), C-reactive protein (CRP) and homocysteine, and differences in these parameters were investigated in relation to plasma concentrations of OLA and DMO.Results: Lower plasma DMO concentrations were associated with higher glucose and TG levels and homeostasis model assessment of insulin resistance (HOMA-IR), while higher plasma OLA concentrations were associated with higher CRP and homocysteine levels in the OLA-treated patients with schizophrenia.Conclusion: These results demonstrate that OLA and its metabolite DMO may have different effects on OLA-induced metabolic abnormalities. DMO might have a counteracting effects on glucose-insulin homeostasis and lipid metabolic abnormalities, which suggests that regular measure of various metabolic parameters and drug monitoring on both OLA and DMO are recommended in OLA-treated patients with schizophrenia.
- 21 June 2022
- Published by Frontiers Media SA in Frontiers in Psychiatry
- Vol. 13, 930457
Open AccessRelationship Between Plasma Olanzapine and N-Desmethyl-Olanzapine Concentration and Metabolic Parameters in Patients With Schizophrenia
Objectives: The aim of the present study was to investigate a potential relationship between metabolic parameters and steady-state plasma concentrations of olanzapine (OLA) and its metabolite, 4-N'-desmethyl-olanzapine (DMO) in patients with schizophrenia taking therapeutic doses.Methods: A total of 352 inpatients, diagnosed with schizophrenia according to the DSM-V criteria and treated with OLA, were investigated. The plasma concentrations of OLA and DMO were measured by high-performance liquid chromatography-mass spectrometry (HPLC-MS/MS). Fasting blood samples were measured for insulin, glucose, total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-c), low-density lipoprotein cholesterol (LDL-c), C-reactive protein (CRP) and homocysteine, and differences in these parameters were investigated in relation to plasma concentrations of OLA and DMO.Results: Lower plasma DMO concentrations were associated with higher glucose and TG levels and homeostasis model assessment of insulin resistance (HOMA-IR), while higher plasma OLA concentrations were associated with higher CRP and homocysteine levels in the OLA-treated patients with schizophrenia.Conclusion: These results demonstrate that OLA and its metabolite DMO may have different effects on OLA-induced metabolic abnormalities. DMO might have a counteracting effects on glucose-insulin homeostasis and lipid metabolic abnormalities, which suggests that regular measure of various metabolic parameters and drug monitoring on both OLA and DMO are recommended in OLA-treated patients with schizophrenia.